Перейти
на сайт журнала "Врач" |
Перейти на сайт журнала "Медицинская сестра"
|
Перейти на сайт журнала "Фармация"
|
Перейти на сайт журнала "Молекулярная медицина"
|
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
|
Журнал включен в российские и международные библиотечные и реферативные базы данных
ВАК (Россия)
|
РИНЦ (Россия)
|
Эко-Вектор (Россия)
|
DEVELOPMENT AND VALIDATION OF A SPECTROPHOTOMETRIC METHOD FOR THE QUANTITATIVE ANALYSIS OF THE SUBSTANCE OF A NEW BIOLOGICALLY ACTIVE COMPOUND 3-[2-OXO-2-(4-PHENYL-1-PIPERAZINYL)ETHYL]-4(3H)-QUINAZOLINONE
DOI: https://doi.org/10.29296/25877313-2020-04-08
Issue:
4
Year:
2020
The purpose of the work is to study the possibility of using spectrophotometry in the UV region for the quantitative determination of a previously un-studied substance of 3- [2- (4-phenyl-1-piperazino) -2-oxoethyl] -quinazolin-4 (3H) -one (VMA-10 -21), as well as the development and validation of methods for its quantitative determination. Material and methods. In the course of the experiment, the analytical equipment was used: spectrophotometer SF-56, analytical balance RADWAG AS 220/C/2, measuring dishes of the 1st accuracy class. The optical density of the test solutions was measured at a wavelength of 275 nm in cu-vettes with a layer thickness of 10 mm. As a comparison solution used 1% solution of hydrochloric acid. Validation of the presented methodology was carried out according to indicators: linearity, precision and correctness. Processing of the experimental data was carried out according to OFS.1.1.0013.15 GF XIV edition. The specific absorption index was calculated using a standard sample of substance VMA-10-21, the purity of which was proved using the HPLC method. Results. The spectrum of the substance VMA-10-21 in the ultraviolet region was represented by two absorption bands with maxima at wavelengths of 235 and 275 nm. The use of a wavelength at a wavelength of 275 nm is justified. The specific absorption index at the selected wavelength was calcu-lated. A quantitative determination technique has been developed which, according to validation parameters, linearity, precision and correctness com-plies with the requirements of OFS.1.1.0012.15 GF of the XIV edition. Conclusions. The possibility of using spectrophotometry in the UV region for the quantitative determination of the substance VMA-10-21 was studied. A spectrophotometric method for the quantitative determination of the basic substance in the substance VMA-10-21 was developed and validated.
Keywords:
spectrophotometry
quinazoline derivative
quantification
validation
References:
- Il'nickij A., Proshchaev K. Vozrastno-situacionnaya depressiya. Vrach. 2018; 29(9): 48-49.
- Wittchen Н., Jacobi F., Rehm J. The size and burden of mental disorders and other disorders of the brain in Europe 2010 // Eur. Neuropsychopharmacol. 2011; 21(9):655679.
- Kodonidi I.P. Molekulyarnoe konstruirovanie i tselenapravlennyui sintezз N-zameshchennyukh proisvodnyukh 4-okso-1,4-digidropirimidina na osnove tormoznyukh neiromediatorov. Khimiko-farmatsevticheskii zhurnal. 2009; 43(10):3239.
- Patent № 2507199 (RF). Proizvodnyue khinazolina, obladayushchie antidepressivnoi i anksioliticheskoi aktivnostyu. Opubl. 20.02.2014. 12 s.
- Vlasov I.V. Zavodskaya laboratoriya. Diagnostika materialov. Spektrofotometricheskie metody v analize lekarstvennykh preparatov. 2011; 1:21.
- Gendugov T.A. Evraziiskii soyuz uchenykh. 2019; 11-2 (68):4647.
- Gosudarstvennaya Farmakopeya Rossiiskoi Federatsii. Izd. XIV. Т. 1. М. 2016. [Elektronnyi resurs]. Rezhim dostupa: http://feml.scsml.rssi.ru/feml
- Gavrilin M.V., Senchenko S.P. Validatsiya analiticheskilh metodik (metodicheskie ukaazaniya dlya aspirantov i studentov). GOU VPO Pyatigorskaya GFA Roszdrava. Pyatigorsk. 2008. 37 s.